
Hepanib200 mg
Everest Pharmaceuticals Ltd.
Sorafenib Tosylate is an oral multi-targeted tyrosine kinase inhibitor with the following evidence-based indications: Established / Approved uses Unresectable hepatocellular carcinoma (HCC):…
Sorafenib Tosylate is an oral multi-targeted tyrosine kinase inhibitor with the following evidence-based indications:
Sorafenib Tosylate is not indicated for medullary or anaplastic thyroid cancer, and is not established for use in children.
| Indication | Adult dose |
|---|---|
| Unresectable hepatocellular carcinoma | 400 mg (two 200 mg tablets) orally twice daily, continued until lack of clinical benefit or unacceptable toxicity |
| Advanced renal cell carcinoma | 400 mg (two 200 mg tablets) orally twice daily, continued until lack of clinical benefit or unacceptable toxicity |
| Radioactive-iodine-refractory differentiated thyroid carcinoma | 400 mg (two 200 mg tablets) orally twice daily, continued until lack of clinical benefit or unacceptable toxicity |
Take Sorafenib Tosylate tablets on an empty stomach, at least 1 hour before or 2 hours after a meal, and swallow whole with a full glass of water. Avoid taking with a high-fat meal, as this reduces absorption.
For adverse reactions such as hand-foot skin reaction, hypertension, or other significant toxicity, the physician may interrupt therapy and/or reduce the dose in a stepwise manner, typically first to 400 mg once daily, and further to 400 mg every other day, according to severity.
No dose adjustment is required in patients with mild to moderate hepatic impairment (Child-Pugh A or B). Data in severe hepatic impairment (Child-Pugh C) are limited; use with caution and close monitoring.
No dose adjustment is generally required in mild-to-moderate renal impairment. Data in severe renal impairment or patients on dialysis are limited; use with caution.
Side effects of Sorafenib Tosylate range from common dermatologic and gastrointestinal effects to rare but serious systemic toxicities.
Sorafenib Tosylate is contraindicated in patients with known hypersensitivity to sorafenib, sorafenib tosylate, or to any excipient of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.